Puma Biotechnology (PBYI) Prepaid Assets (2011 - 2026)
Puma Biotechnology's (PBYI) quarterly Prepaid Assets came in at $3.4 million in Q1 2026, up 3374.49% YoY from $98000.0 in Q1 2025, and up 201.86% on a QoQ basis from $1.1 million in Q4 2025.
Analysis
Puma Biotechnology (PBYI) Prepaid Assets (2011 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 16 years of Prepaid Assets data on file, last reported at $3.4 million in Q1 2026.
- Quarterly Prepaid Assets rose 3374.49% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 3374.49% YoY) and the FY2025 annual result came in at $1.1 million, up 1139.56% from the prior year.
- Prepaid Assets advanced to $3.4 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $8.6 million in Q2 2022 to a low of $91000.0 in Q4 2024.
- A 5-year average of $1.8 million and a median of $1.4 million in 2023 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2024 — Prepaid Assets slumped 93.51% — and 2026, when it soared 3374.49%.
- Tracing PBYI's Prepaid Assets over 5 years: stood at $2.4 million in 2022, then slumped by 42.24% to $1.4 million in 2023, then slumped by 93.51% to $91000.0 in 2024, then soared by 1139.56% to $1.1 million in 2025, then surged by 201.86% to $3.4 million in 2026.
- The last three Prepaid Assets figures came in at $3.4 million (Q1 2026), $1.1 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Puma Biotechnology | 486.99 Mn | 393.08 Mn | 44.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.59 Mn |
| Mar 31, 2026 | 3.41 Mn |
| Dec 31, 2025 | 3.64 Mn |
| Sep 30, 2025 | 3.83 Mn |
| Jun 30, 2025 | 3.89 Mn |
| Mar 31, 2025 | 5.32 Mn |
| Dec 31, 2024 | 5.87 Mn |
| Sep 30, 2024 | 2.54 Mn |
| Jun 30, 2024 | 3.49 Mn |
| Mar 31, 2024 | 3.92 Mn |
| Dec 31, 2023 | 4.42 Mn |
| Sep 30, 2023 | 3.68 Mn |
| Jun 30, 2023 | 4.62 Mn |
| Mar 31, 2023 | 5.03 Mn |
| Dec 31, 2022 | 5.90 Mn |
| Sep 30, 2022 | 6.80 Mn |
| Jun 30, 2022 | 8.58 Mn |
| Mar 31, 2022 | 8.72 Mn |
| Dec 31, 2021 | 8.98 Mn |
| Sep 30, 2021 | 9.07 Mn |